Streetbeat News

Earnings

MRNA

Moderna Inc (NASDAQ:MRNA) announced that its next-generation COVID-19 vaccine, mRNA-1283, met the primary endpoints in its Phase 3 trial, showing a higher immune response than its current vaccine, mRNA-1273.222. The vaccine demonstrated effectiveness against the Omicron BA.4/BA.5 and original virus strains, particularly in individuals over 65. mRNA-1283 has a similar safety profile to Moderna's approved vaccines and offers benefits in storage and accessibility. Detailed Phase 3 data will be shared at Moderna's Vaccines Day and upcoming conferences. MRNA shares dropped 1.36% to $108.88.

Portfolio Pulse from Vandana Singh

March 26, 2024 | 4:39 pm

BKKT

Bakkt Holdings shares are trading lower following the announcement of their Q4 financial results, which did not meet expectations.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:39 pm

TFC

Recent analysis of Truist Finl (NYSE:TFC) options trading shows a bearish trend among financial giants, with 54% displaying bearish tendencies and 45% bullish. The analysis highlighted 11 unusual trades, including 9 puts and 2 calls, with a focus on a price range of $35.0 to $40.0 for TFC over the last 3 months. The largest trades included both bullish and bearish sentiments, with significant open interest and volume in options within the $35.0 to $40.0 strike price range. Truist Finl, a regional bank resulting from the merger of BB&T and SunTrust, has seen its stock price increase by 0.72% to $37.87, with an RSI indicating it may be approaching overbought territory. An earnings announcement is expected in 27 days, and an analyst from Stephens & Co. has set a price target of $43.0, upgrading the stock to Overweight.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:30 pm

HOOD

Robinhood Markets Inc (NASDAQ:HOOD) is drawing attention due to a scheduled livestream event titled 'The New Gold Standard' by CEO Vlad Tenev, promising 'exciting updates'. This follows recent positive performance, with stock up over 50% YTD and nearly 20% in the last month. February metrics showed growth in customers and trading volumes across all asset classes. Analysts anticipate earnings of 4 cents per share on revenue of $525.432 million in the next report.

Portfolio Pulse from Adam Eckert

March 26, 2024 | 4:20 pm

LNG

Cheniere Energy Inc. (NYSE:LNG) stock is currently trading at $161.00, marking a 0.58% increase. Over the past month and year, the stock has risen by 4.41% and 2.86%, respectively. Its P/E ratio of 3.93 is significantly lower than the industry average of 15.96, suggesting potential undervaluation or weaker growth prospects compared to its peers in the Oil, Gas & Consumable Fuels industry.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:15 pm

EQ

Equillium's stock is trading lower following the announcement of its Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:11 pm

APCX

CDLX

GDS

MESO

MKC

OPGN

STOK

U.S. stocks saw gains with the Dow Jones up by 100 points. McCormick & Co Inc reported better-than-expected Q1 results, with sales growth of 3% and an adjusted EPS of 63 cents. Stoke Therapeutics, Mesoblast Ltd, and OpGen Inc saw significant share price increases due to positive developments. Conversely, Cardlytics Inc, GDS Holdings Ltd, and AppTech Payments Corp experienced notable declines in their share prices.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 4:08 pm

LGMK

LogicMark (NASDAQ:LGMK) is anticipated to report a Q1 2024 EPS of $-1.73 on March 27, 2024. Investors are keen on whether the company will surpass this estimate and provide positive future guidance. Historically, LogicMark's stock price has been sensitive to earnings outcomes and guidance. The stock is currently trading at $1.01, reflecting a 74.62% decline over the last year, indicating investor concern ahead of the earnings report.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:02 pm

DLNG

Dynagas LNG Partners (NYSE:DLNG) is scheduled to release its quarterly earnings report on March 27, 2024. Analysts predict an EPS of $0.30. The company's past earnings performance shows a mix of misses and beats, with the share price reacting variably. Shares are currently trading at $2.8, down 2.86% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm

DRRX

Durect Corporation (NASDAQ:DRRX) is scheduled to release its quarterly earnings report on March 27, 2024, with analysts expecting an EPS of $-0.33. The company's past performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. However, Durect's stock has declined by 70.14% over the last year, indicating a bearish outlook among long-term shareholders. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm